Hydrochloric Acid

Hydrochloric Acid

SCHEMBL1370752

CN(C)CCN(C)C.[Cl-].[Cl-].[Zn+2]

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 known ✓ P08172 1/20 0.30
CHRM1 known ✓ P11229 1/20 0.30
CHRM3 known ✓ P20309 1/20 0.30
CA12 O43570 1/20 0.61
CA2 P00918 1/20 0.61
CA3 P07451 1/20 0.61
CA4 P22748 1/20 0.61
CA6 P23280 1/20 0.61
CA5A P35218 1/20 0.61
CA7 P43166 1/20 0.61
CA9 Q16790 1/20 0.61
CA14 Q9ULX7 1/20 0.61
CA5B Q9Y2D0 1/20 0.61
ALDH1A1 P00352 2/20 0.50
TSHR P16473 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
MAPT P10636 1/20 0.47
PRMT3 O60678 1/20 0.41
CARM1 Q86X55 1/20 0.41
PRMT6 Q96LA8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6743343 0.90 CA12 (0.61) CA12CA2CA3CA4CA6
Hydrochloric Acid SCHEMBL8310418 0.90 CA12 (0.61) CA12CA2CA3CA4CA6
Hydrochloric Acid SCHEMBL2829185 0.90 CA12 (0.61) CA12CA2CA3CA4CA6
Hydrochloric Acid SCHEMBL4527188 0.90 CA12 (0.61) CA12CA2CA3CA4CA6
Hydrochloric Acid SCHEMBL10631334 0.90 CA12 (0.61) CA12CA2CA3CA4CA6
Hydrochloric Acid SCHEMBL27676803 0.90
Hydrochloric Acid SCHEMBL28720129 0.90 CA12 (0.61) CA12CA2CA3CA4CA6
Hydrochloric Acid SCHEMBL28208260 0.90 CA12 (0.61) CA12CA2CA3CA4CA6
SCHEMBL10425918 0.89 CA12 (0.73) CA12CA2CA3CA4CA6
SCHEMBL4658729 0.89

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118420424-B Synthesis method of diaryl sulfoxide derivative 夏禾科技(江苏)有限公司 2024-12-27 CN claimed
CN-118420424-A Synthesis method of diaryl sulfoxide derivative 夏禾科技(江苏)有限公司 2024-08-02 CN claimed
CN-118420424-B Synthesis method of diaryl sulfoxide derivative 夏禾科技(江苏)有限公司 2024-12-27 CN disclosed
CN-118420424-A Synthesis method of diaryl sulfoxide derivative 夏禾科技(江苏)有限公司 2024-08-02 CN disclosed
CN-116874416-A Preparation method of 4-iodo-3-methoxypyridine 南京合巨药业有限公司 2023-10-13 CN disclosed
EP-3555095-B1 INHIBITORS OF INFLUENZA VIRUS REPLICATION AND USES THEREOF SUNSHINE LAKE PHARMA CO LTD (CN) 2023-04-12 EP disclosed
US-11342511-B2 Azoline ring-containing compound, electron transport/injection layer material containing the same, and organic electroluminescent element using the same SK MATERIALS JNC CO., LTD. (KR) 2022-05-24 US disclosed
CN-107531641-B Material for transporting electrons, organic electroluminescent element, and display device or lighting device 爱思开新材料捷恩智株式会社 2022-03-15 CN disclosed
CN-107501023-B Method for preparing halogenated (hetero) arene 辽宁大学 2020-08-25 CN disclosed
CN-107266481-B Material for organic electroluminescent element, display device, and lighting device 捷恩智株式会社 2020-04-14 CN disclosed
US-20190214575-A1 MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, DISPLAY DEVICE, AND LIGHTING DEVICE JNC CORPORATION (JP) 2019-07-11 US disclosed
US-20100185019-A1 CATALYST COMPOSITION AND PROCESS FOR PRODUCING CROSS-COUPLED COMPOUND USING SAME TOSOH FINECHEM CORPORATION (JP) 2010-07-22 US disclosed
EP-2168680-A1 CATALYST COMPOSITION AND METHOD FOR PRODUCING CROSS-COUPLING COMPOUND USING THE SAME Kyoto University (JP) 2010-03-31 EP disclosed
US-7569694-B2 Coumarin compound, material for light emitting device and organic electroluminescent device CHISSO CORPORATION (JP) 2009-08-04 US disclosed
US-20090134780-A1 Electron transport material and organic electroluminescent device using the same SK MATERIALS JNC CO., LTD. (KR) 2009-05-28 US disclosed
US-20070176544-A1 Coumarin compound, material for light emitting device and organic electroluminescent device JNC CORPORATION (JP) 2007-08-02 US disclosed
US-20040024216-A1 HMG-CoA reductase inhibitors and method ROBL JEFFREY A (US) 2004-02-05 US disclosed
US-6620821-B2 Tricyclic imine or amine oxime derivative; may be used in combination with one or more hypolipidemic agents or lipid-lowering agents or lipid agents or lipid modulating agents, and/or one or more other types of therapeutic agents BRISTOL-MYERS SQUIBB COMPANY 2003-09-16 US disclosed
US-20020061901-A1 HMG-CoA reductase inhibitors and method BRISTOL-MYERS SQUIBB COMPANY 2002-05-23 US disclosed
US-20020028826-A1 HMG-CoA reductase inhibitors and method BRISTOL-MYERS SQUIBB COMPANY 2002-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020061901-A1 HMG-CoA reductase inhibitors and method HMGCR, LDLR, NR1H2 CHRM2 1411/4885CHRM1 1487/4885CHRM3 1540/4885
US-11342511-B2 Azoline ring-containing compound, electron transport/injection layer material containing the same, and organic electroluminescent element using the same SLC7A5, EML4, ARNT CHRM2 912/4885CHRM1 344/4885CHRM3 683/4885
US-20020028826-A1 HMG-CoA reductase inhibitors and method HMGCR, LDLR, NR1H2 CHRM2 1494/4885CHRM1 1544/4885CHRM3 1618/4885
US-20190214575-A1 MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, DISPLAY DEVICE, AND LIGHTING DEVICE L1CAM, VDAC1, VDAC2 CHRM2 396/4885CHRM1 228/4885CHRM3 713/4885
US-20040024216-A1 HMG-CoA reductase inhibitors and method HMGCR, LDLR, NR1H2 CHRM2 1381/4885CHRM1 1505/4885CHRM3 1697/4885
US-20090134780-A1 Electron transport material and organic electroluminescent device using the same SLC25A11, ELAVL1, SLC26A3 CHRM2 1490/4885CHRM1 1115/4885CHRM3 1750/4885
US-20070176544-A1 Coumarin compound, material for light emitting device and organic electroluminescent device TRPA1, CYP3A4, UGT1A10 CHRM2 1193/4885CHRM1 617/4885CHRM3 577/4885
US-20100185019-A1 CATALYST COMPOSITION AND PROCESS FOR PRODUCING CROSS-COUPLED COMPOUND USING SAME PYM1, CHRM2, CHRM1 CHRM2 2/4885CHRM1 3/4885CHRM3 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.